Results 11 to 20 of about 491,626 (323)

Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.

Cancer Discovery, 2021
Combining venetoclax, a selective BCL-2 inhibitor, with low-dose navitoclax, a BCL-XL/BCL-2 inhibitor, may allow targeting of both BCL-2 and BCL XL without dose-limiting thrombocytopenia associated with navitoclax monotherapy.
V. Pullarkat, Norman J. Lacayo, E. Jabbour, J. Rubnitz, A. Bajel, T. Laetsch, Jessica T. Leonard, Susan I. Colace, S. Khaw, S. Fleming, R. Mattison, R. Norris, J. Opferman, K. Roberts, Yaqi Zhao, Chunxu Qu, Mohamed Badawi, Michelle Schmidt, Bo Tong, John C. Pesko, Yan Sun, J. Ross, D. Vishwamitra, Lindsey Rosenwinkel, S. Y. Kim, A. Jacobson, C. Mullighan, Thomas B. Alexander, W. Stock   +28 more
semanticscholar   +1 more source

Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

Frontiers in Pediatrics, 2022
Pediatric Acute Lymphoblastic Leukemia (ALL) cure rates have improved exponentially over the past five decades with now over 90% of children achieving long-term survival.
L. Maese, R. Rau
semanticscholar   +1 more source

Sellar B lymphoblastic lymphoma mimics pituitary apoplexy with newly discovered gene mutations in TP53 and PAX5: A case report

Frontiers in Oncology, 2023
Lymphoblastic lymphoma (LBL) is a rare tumor that accounts for approximately 2-4% of all non-Hodgkin lymphomas, and less than 20% of LBLs are derived from B cells.
Yi Wang, Yajun Yang, Qiuxia Wang, Ce Wang, Xinjuan Xu, Dongao Wang, Feirong Bai, Panpan Li, Xintao Huang   +8 more
doaj   +1 more source

Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells

Stem Cell Reviews and Reports, 2021
While treatment for B-cell malignancies has been revolutionized through the advent of CAR immunotherapy, similar strategies for T-cell malignancies have been limited. Additionally, T-cell leukemias and lymphomas can commonly metastasize to the CNS, where
Jia Feng, Haichan Xu, Andrew Cinquina, Zehua Wu, Qi Chen, Ping Zhang, Xingen Wang, Huiming Shan, Lei Xu, Qian Zhang, Lihua Sun, Wenli Zhang, K. Pinz, M. Wada, Xun Jiang, William M. Hanes, Yupo Ma, Hongyu Zhang   +17 more
semanticscholar   +1 more source

Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Cancers, 2021
Simple Summary Pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoma (LBL) currently have unsatisfactory outcomes, and novel treatment options are needed.
Amber Gibson, Adriana Trabal, D. McCall, S. Khazal, Laurie Toepfer, D. Bell, Michael Roth, K. Mahadeo, C. Nunez, N. Short, C. Dinardo, M. Konopleva, G. Issa, F. Ravandi, N. Jain, G. Borthakur, H. Kantarjian, E. Jabbour, Branko Cuglievan   +18 more
semanticscholar   +1 more source

Salvage Therapy in Early Relapse of T-Lymphoblastic Leukemia/Lymphoma Using Daratumumab/Nelarabine Combination: Two Consecutive Cases

Case Reports in Hematology, 2022
Treatment of early relapses of T lymphoblastic leukemia/lymphoma is often unsuccessful. We tested an experimental regimen containing daratumumab and nelarabine in two young patients with early relapses of T lymphoblastic lymphoma and T-ALL, respectively.
Ingolf Molle, Irma Petruskevicius, Peter Kamper, Francesco d’Amore   +3 more
doaj   +1 more source

Lymphoblastic lymphoma in adults [PDF]

Cancer, 1981
Clinical and cytogenetic studied were done on 12 patients with lymphoblastic lymphoma. The ages of the patients ranged from 17 to 58 years (median, 24.5 years). Males predominated by a ration of 5:1. Ten of the 12 patients had a mediastinal mass at diagnosis; two thirds of the patients had involvement of the bone marrow (3 of 12 patients initially were
R A, Streuli, Y, Kaneko, D, Variakojis, A, Kinnealey, H M, Golomb, J D, Rowley   +5 more
openaire   +2 more sources

Extranodal Biphenotypic Non-Hodgkin Lymphoma of the Popliteal Cavity: A Case Report and Review of Literature

Diagnostics, 2022
Primary soft-tissue lymphoma (PSTL) is a rare extranodal non-Hodgkin lymphoma, characterized by a mass growing within soft-tissue, which is connective tissue, adipose tissue, and skeletal muscle.
Giulia A. Restivo, Lara Mussolin, Paolo D’Angelo, Angelica Zin, Martina Pigazzi, Elisa Carraro, Emanuele S. G. D’Amore, Marta Pillon, Piero Farruggia   +8 more
doaj   +1 more source

Malignant lymphoma, lymphoblastic [PDF]

Cancer, 1976
Among the malignant lymphomas of the diffuse, poorly differentiated lymphocytic type, a cytologically distinctive form can be recognized. It is composed of immature lymphoid cells that are indistinguishable from the cells of acute lymphoblastic leukemia (ALL).
B N, Nathwani, H, Kim, H, Rappaport
openaire   +2 more sources

The chemotherapy of lymphoblastic lymphoma [PDF]

Blood, 1981
Abstract Thirty-two patients treated on consecutive Southwest Oncology Group (SWOG) protocols for malignant lymphoma were subsequently diagnosed as having lymphoblastic lymphoma. Combination chemistry, usually adriamycin-based, produced complete responses (CR) in 17 patients (53%). Median survival was 15 mo.
J B, Voakes, S E, Jones, E M, McKelvey
openaire   +3 more sources